Thoma Kikis
Thoma Kikis is an American-born Greek film producer, designer, typographer and entrepreneur best known for co-founding Kannalife Sciences, Neuropathix and the founder of TEKNIKE.
Thoma Kikis

Proze · CC BY-SA 4.0
- Name
- Thoma Kikis
- Birthplace
- New York City
- Education
- * NYU
- Occupation
- * filmmaker
- Born
- 1901
- Nationality
- United States
Reference Check
Propose documentary evidence for Thoma Kikis. A contribution is never written directly as fact: identity, source, rights and evidence gates still decide.
Sign in to contribute
World of VALÉORINE
Documentary connections
Only confirmed graph relationships appear here. Images are shown only when their identity and reuse rights both pass the documentary gate.
Documentary evidence
Documentary basis
Authority files
wikidata · Q7786761 · wikipedia · Thoma Kikis
In this article
Key facts
Key facts
• Name — Thoma Kikis • Native Name — Θωμά Κίκης • Birthplace — New York City • Education — * NYU • NYFA • Occupation — * filmmaker • designer • typographer • entrepreneur
Life
Life
Kikis was born in New York City to Greek parents from the city of Ioannina in the Epirus region of Greece. He studied communications at New York University and filmmaking at the New York Film Academy.
Design and typography
Design and typography
Kikis is the founder of TEKNIKE, a multidisciplinary studio and type foundry focused on experimental and culturally inspired logotypes, brand identity, story and type design. His clients have included MTV, Hulu, and Hermès. He has released numerous typefaces that span geometric, monospaced, script, and display styles, often incorporating Latin and Greek scripts, with most supporting Cyrillic and some Hebrew alphabets. His first major release, Fugues (2015), is a textured geometric monospaced sans-serif inspired by organic architecture geometry as apparent in the work of Antoni Gaudi. In 2016, he introduced Ithaka, a script typeface, followed by several releases in 2017, including the hand-lettered Anamorphic, Evangelos, Privé, and Qipao. That year, he also developed Nautis, a sans serif influenced by nautical themes; Jadeite, a mid-century modern sans; Cycladic, a sans serif inspired by Greek island architecture; Vantagram, a blackletter typeface; UNY, a slab serif designed for athletic lettering; and Designator, a modular monospaced font. In 2019, Kikis expanded his collection with the hand-lettered Omoshiroi, Côte, and Penzance, along with monospaced typefaces such as Monadic, Chartreux, Originator, and the high-contrast sans Quantour. His 2020 releases included the dot matrix typefaces Receptor and Departe, as well as the industrial shipping monospaced Eleusis. Other works include Ermou (2021), a Greek emulation typeface and Telomere (2024) continuing his exploration of typographic design.
Biotechnology
Biotechnology
In 2010, Kikis co-founded Kannalife Sciences, a biopharmaceutical company and subsidiary of Neuropathix, developing cannabinoid-inspired therapeutics to treat neurodegenerative diseases, including Parkinson's disease, CTE and Chemotherapy-induced peripheral neuropathy. In 2014, he appeared on Bloomberg TV's Taking Stock with Pimm Fox discussing forming Kannalife Sciences, cannabinoid research, the regulatory landscape, and Medical cannabis industry in the United States. His efforts have been highlighted in outlets such as the National Herald, Vice Media, and Temple News. In 2021, researchers at Temple University, in collaboration with Kannalife, were awarded a three-year $2.97 Million Small Business Innovation Research grant from the National Institutes of Health to support preclinical studies on KLS-13019, a novel cannabidiol-derived compound. The research focuses on evaluating the compound's potential to protect nerve cells and reduce neuroinflammation, with the goal of addressing CIPN and other neurodegenerative conditions. In July 2024, Kannalife Sciences received a $1.49 million grant from The Michael J. Fox Foundation. This funding aims to advance preclinical research into KLS-13019, a therapeutic targeting neuroinflammation and mitochondrial dysfunction associated with Parkinson's disease.
Typefaces
Typefaces
• 2015 – Fugues • 2016 – Ithaka • 2017 – Evangelos, Anamorphic, Cycladic, Designator, Nautis, Privé, Qipao, Jadeite, Vantagram, UNY • 2019 – Omoshiroi, Cote, Penzance, Monadic, Chartreux, Originator, Quantour • 2020 – Receptor, Departe, Eleusis • 2021 – Ermou • 2024 – Telomere
Film
Film
In 2003, Kikis co-founded Ovie Entertainment to develop and produce motion picture intellectual properties. His first project was as producer of Darkon (2006), the award-winning feature-length documentary film following the real-life adventures of a group of fantasy live-action role-playing (LARP) gamers, which won the Audience Award for Best Documentary at the 2006 South By Southwest (SXSW) Film Festival. He later co-produced the award-winning Alps (2011), directed by Yorgos Lanthimos and winner of the Golden Osella Award for Best Screenplay (Yorgos Lanthimos and Efthimis Filippou) at the 68th Venice International Film Festival. In 2012, he worked on the art-house black comedy film It's A Disaster (2012) written and directed by Todd Berger and stars Julia Stiles, David Cross, Jeff Grace and America Ferrera. Subsequent works include the experimental short film A Stone Appears (2016), featuring Bill Skarsgård, and Man in the Attic (2021). He serves on the board of the Hellenic Film Society and led the creative direction for the rebranding initiative—designing the Society’s new main logo and the creation of the official poster for the 2025 New York Greek Film Expo—a richly layered, hand-illustrated design produced in collaboration through his New York–based studio TEKNIKE. He is a member of the Hellenic Film Academy.
Feature films
Feature films
• 2006 — Darkon (producer, executive producer) • 2011 — Alps (co-producer) • 2012 — It's A Disaster (executive producer) • 2021 — Man in the Attic (co-executive producer)
Short films
Short films
• 2016 — A Stone Appears (executive producer)
Primary material
Documents and archives
reference work
- “Thoma Kikis”, English Wikipedia, consulted as further reading
Reputable secondary · Wikipedia
institutional register
- Wikidata, structured authority record Q7786761: Thoma Kikis
General reference · Wikimedia Foundation
Text attribution
Licensing
Text attribution
Part of the biographical narrative on this page reuses licensed material. Its origin, revision and licence are recorded here.
The biographical narrative on this page is based on the Wikipedia article Thoma Kikis, revision 1342701088 (EN edition), by its contributors. VALÉORINE has edited that text and built its own documentary record around it. The reused material is available under CC BY-SA 4.0, and this page's reuse of it is offered under the same licence. Everything else on this page — the chronology, the holdings, the evidence, the plates and the connections — is VALÉORINE's own record. Sources and licences.
Notes from the source article
Cited by Wikipedia
Notes from the source article
These works are cited by the source article, in its own numbering. They are recorded as its citations, not as sources VALÉORINE has verified.
- 1.Guion, Payton. The NFL's Anti-Weed Policy Even Extends to Drugs That Could Prevent Brain Damage. VICE News. November 12, 2014.
- 2.Ελπιδοφόρα έρευνα από φαρμακευτική εταιρεία ομογενών. Ethnikos Kirikas. September 28, 2021.
- 3.TEKNIKE Foundry. MyFonts.
- 4.Greek-Americans Advance Medical Marijuana Legalization. New Greek TV. August 14, 2014.
- 5.Official Awards of the 68th Venice Film Festival. La Biennale di Venezia. 13 November 2024.
- 6.About Us. Hellenic Film Society.
- 7.The National Herald. Hellenic Film Society Unveils New Logo as Part of Exciting Rebranding.
- 8.Hellenic Film Society Unveils New Poster and Identity for 2025 New York Greek Film Expo. The National Herald. July 16, 2025.
- 9.Members. Hellenic Film Academy.
- 10.Thoma Kikis. Fonts In Use.
- 11.Queens Gazette. Hellenic Film Society Unveils New Logo.
- 12.Thoma Kikis - Designer. Luc Devroye Typography.
- 13.Thoma Kikis Fonts. MyFonts.
- 14.Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS). Biospace. 28 September 2021.
- 15.How cannabis is helping one company research treatment of CTE. Sports Illustrated. July 12, 2016.
- 16.Cannabis biotech companies see new opportunities to raise capital. Crain’s New York Business. June 2018.
- 17.Thoma Kikis discusses cannabinoid research on Bloomberg TV. Bloomberg.
- 18.The National Herald. Kikis and Colleagues Mine Cannabis for Medical Innovation. 17 September 2014.
- 19.CBD-like molecule could lower pain from chemo. Temple News. 25 February 2020.
- 20.With New NIH Small Business Innovation Research Award, Temple Researchers Set to Test Novel Cannabis Analog in Preclinical Studies. Temple Health. September 29, 2021.
- 21.Lobo, Andrea. MJFF $1.49M grant to advance preclinical research into KLS‑13019. Parkinsons News Today. July 1, 2024.
References
Citations
References
Each reference names the institution holding it, so a reader may go to the document itself.
reference work
Secondary witnessinstitutional register
Wikidata, structured authority record Q7786761: Thoma KikisWikimedia Foundation
General reference
The Encyclopedia exists whether or not anything is for sale. Corrections are recorded rather than overwritten, and every version of this record is kept. Published 17 August 2026.
Elsewhere in Modern design
3,254 published records in this field, each with its sources named.
- Theodoros StamosDesigner
- Thérèse DePrezDesigner
- Theyre Lee-ElliottDesigner
- Thierry CoupDesigner
- Thomas AndrewsDesigner
- Thomas Aquinas MaguireDesigner
- Thomas BachemDesigner
- Thomas BickhamDesigner
Best supported in this field
For owners
Own a work by Thoma Kikis?
A specialist will read what you send and tell you what the house can establish, what it cannot, and whether the object is suited to sale. There is no charge and no obligation. The object stays with you throughout; nothing is shipped to us unless it is arranged in writing beforehand.